Not "USAMRIID" - should read "WRAIR" and "EbolaCide" should read "DengueCide":
[SNIP] With this funding, the Walter Reed Army Institute of Research (WRAIR) would challenge specially bred mice with all four serotypes of the dengue fever pathogen, apply an anti-viral treatment prepared by NanoViricides, Inc., and measure the results. Assuming favorable results in these trials, WRAIR would challenge nonhuman primates with varying amounts and serotypes of Dengue pathogen and then treat with varying dose levels of anti-viral treatment. WRAIR would also arrange and implement toxicity experiments on the NanoViricides, Inc. drug candidates. WRAIR would analyze the results so as to determine the value of filing an Investigational New Drug (IND) application and readying drug candidates for human trials.
NanoViricides, Inc. would be the nongovernment recipient of this funding. The company would receive these funds through a contract with WRAIR, which would manage the Department of Defense dollars. The dollars would be spent partly by WRAIR to cover overhead, lab tech and specialist time. NanoViricides, Inc. would be compensated for its expertise, a certain amount of overhead, bench time preparing the drugs and the actual NanoViricides, Inc. drug materials.
This research, if successful, would provide a direct benefit to active-duty, reserve and national guard troops stationed in Puerto Rico and to troops deployed to the various regions of the world where Dengue is endemic. An effective drug would obviously also have major benefits for the civilian population in Puerto Rico.
News 
Market Data 
Discover 
